Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 8 (2011), Issue 4 (April)

1. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.
   Ann Rheum Dis, 70(5): 823-6. [Abstract] [Full-text]
2. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes.
   Ann Rheum Dis, 70(5): 727-32. [Abstract] [Full-text]
3. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction.
   Ann Rheum Dis, 70(5): 733-9. [Abstract] [Full-text]
4. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.
   Ann Rheum Dis, 70(5): 785-91. [Abstract] [Full-text]
5. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study.
   Ann Rheum Dis, 70(5): 812-7. [Abstract] [Full-text]
6. Changes in the cervical spine of children with juvenile idiopathic arthritis evaluated with lateral cephalometric radiographs: a case control study.
   Angle Orthod, 81(3): 447-52. [Abstract] [Full-text]
7. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments.
   Ann Rheum Dis, 70(5): 792-8. [Abstract] [Full-text]
8. Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.
   Ann Rheum Dis, 70(5): 858-63. [Abstract] [Full-text]
9. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
   Ann Rheum Dis, 70(5): 755-9. [Abstract] [Full-text]
10. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase.
    Ann Rheum Dis, 70(5): 772-7. [Abstract] [Full-text]
11. Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice.
    Ann Rheum Dis, 70(5): 844-50. [Abstract] [Full-text]
12. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
    Ann Rheum Dis, 70(5): 747-54. [Abstract] [Full-text]
13. Progression of cervical spine instabilities in rheumatoid arthritis: a prospective cohort study of outpatients over 5 years.
    Spine (Phila Pa 1976), 36(8): 647-53. [Abstract] [Full-text]
14. Non-invasive screening of progressive joint defects in the Type II collagen-induced arthritis animal model using radiographic paw images.
    Inflamm Res, 60(5): 447-56. [Abstract] [Full-text]
15. IL-33: a promising therapeutic target for rheumatoid arthritis?
    Expert Opin Ther Targets, 15(5): 529-34. [Abstract] [Full-text]
16. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis.
    J Lipid Res, 52(5): 1023-32. [Abstract] [Full-text]
17. Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.
    Arch Intern Med, 171(7): 657-67. [Abstract] [Full-text]
18. Pectenotoxin-2 induces G1 arrest of the cell cycle in synovial fibroblasts of patients with rheumatoid arthritis.
    Int J Mol Med, 27(6): 783-7. [Abstract] [Full-text]
19. Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren's syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands.
    Arch Oral Biol, 56(5): 413-20. [Abstract] [Full-text]
20. A genome-wide screen of gene-gene interactions for rheumatoid arthritis susceptibility.
    Hum Genet, 129(5): 473-85. [Abstract] [Full-text]
21. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    JAMA, 305(14): 1460-8. [Abstract] [Full-text]
22. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    JAMA, 305(14): 1460-8. [Abstract] [Full-text]
23. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    JAMA, 305(14): 1460-8. [Abstract] [Full-text]
24. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments.
    Physiol Genomics, 43(7): 365-71. [Abstract] [Full-text]
25. Lumbar radiculopathy caused by foraminal stenosis in rheumatoid arthritis.
    Ups J Med Sci, 116(2): 133-7. [Abstract] [Full-text]
26. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis.
    J Health Psychol, 16(4): 667-77. [Abstract] [Full-text]
27. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis.
    Rheumatology (Oxford), 50(5): 830-7. [Abstract] [Full-text]
28. Diagnostic significance of measuring antibodies to cyclic type 3 muscarinic acetylcholine receptor peptides in primary Sjogren's syndrome.
    Rheumatology (Oxford), 50(5): 879-84. [Abstract] [Full-text]
29. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis.
    Rheumatology (Oxford), 50(5): 962-5. [Abstract] [Full-text]
30. HLA-G and HLA-E in patients with juvenile idiopathic arthritis.
    Rheumatology (Oxford), 50(5): 966-72. [Abstract] [Full-text]
31. Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B.
    Rheumatology (Oxford), 50(5): 852-61. [Abstract] [Full-text]
32. Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk?
    Rheumatology (Oxford), 50(5): 939-43. [Abstract] [Full-text]
33. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN).
    Rheumatology (Oxford), 50(5): 926-31. [Abstract] [Full-text]
34. Osteoclasts in arthritis and Th17 cell development.
    Int Immunopharmacol, 11(5): 543-8. [Abstract] [Full-text]
35. Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger.
    Skeletal Radiol, 40(6): 745-55. [Abstract] [Full-text]
36. Enzyme-linked immunosorbent assay screening then indirect immunofluorescence confirmation of antinuclear antibodies: a statistical analysis.
    Am J Clin Pathol, 135(5): 678-84. [Abstract] [Full-text]
37. Rheumatoid arthritis of the elbow.
    Hand Clin, 27(2): 139-50, v. [Abstract] [Full-text]
38. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.
    Paediatr Drugs, 13(3): 161-73. [Abstract] [Full-text]
39. Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis.
    J Autoimmun, 36(3): 288-300. [Abstract] [Full-text]
40. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms.
    Drug Metab Dispos, 39(5): 803-13. [Abstract] [Full-text]
41. Quantifying synovitis in rheumatoid arthritis using computer-assisted manual segmentation with 3 Tesla MRI scanning.
    J Magn Reson Imaging, 33(5): 1106-13. [Abstract] [Full-text]
42. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Int J Dermatol, 50(5): 619-25. [Abstract] [Full-text]
43. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis.
    Clin Pharmacol Ther, 89(5): 735-40. [Abstract] [Full-text]
44. Celastrus-derived celastrol suppresses autoimmune arthritis by modulating antigen-induced cellular and humoral effector responses.
    J Biol Chem, 286(17): 15138-46. [Abstract] [Full-text]
45. Switching rheumatoid arthritis treatments: an update.
    Autoimmun Rev, 10(7): 397-403. [Abstract] [Full-text]
46. Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus.
    Autoimmun Rev, 10(7): 432-7. [Abstract] [Full-text]
47. The swollen joint, the thickened artery, and the smoking gun: tobacco exposure, citrullination and rheumatoid arthritis.
    Rheumatol Int, 31(5): 567-72. [Abstract] [Full-text]
48. Degree of modification of Ro60 by the lipid peroxidation by-product 4-hydroxy-2-nonenal may differentially induce Sjögren syndrome or systemic lupus erythematosus in BALB/c mice.
    Free Radic Biol Med, 50(10): 1222-33. [Abstract] [Full-text]
49. Overlapping juvenile idiopathic arthritis and systemic lupus erythematosus: a case report.
    Rheumatol Int, 31(5): 695-8. [Abstract] [Full-text]
50. Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis.
    Rheumatol Int, 31(5): 657-65. [Abstract] [Full-text]
51. Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis.
    Rheumatol Int, 31(5): 635-40. [Abstract] [Full-text]
52. Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis.
    Rheumatol Int, 31(5): 617-22. [Abstract] [Full-text]
53. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis.
    Clin Rheumatol, 30(5): 697-701. [Abstract] [Full-text]
54. Three cases of rheumatoid arthritis with laryngeal stridor.
    Clin Rheumatol, 30(5): 723-7. [Abstract] [Full-text]
55. Health-related quality of life in ankylosing spondylitis, fibromyalgia syndrome, and rheumatoid arthritis: a comparison with a selected sample of healthy ındividuals.
    Clin Rheumatol, 30(5): 655-64. [Abstract] [Full-text]
56. Cutaneous nodules in patients with rheumatoid arthritis: a case report and review of literatures.
    Clin Rheumatol, 30(5): 719-22. [Abstract] [Full-text]
57. Atlanto-axial joint of atlanto-axial subluxation patients due to rheumatoid arthritis before and after surgery: morphological evaluation using CT reconstruction.
    Eur Spine J, 20(5): 798-803. [Abstract] [Full-text]
58. The effects of strength and endurance training in patients with rheumatoid arthritis.
    Clin Rheumatol, 30(5): 623-32. [Abstract] [Full-text]
59. Serum cysteine proteases and their inhibitors in rheumatoid arthritis: relation to disease activity and radiographic progression.
    Clin Rheumatol, 30(5): 633-8. [Abstract] [Full-text]
60. Impact of tight control strategy on rheumatoid arthritis in Sarawak.
    Clin Rheumatol, 30(5): 615-21. [Abstract] [Full-text]
61. Anti-inflammatory and anti-nociceptive effect of Betula platyphylla var. japonica in human interleukin-1β-stimulated fibroblast-like synoviocytes and in experimental animal models.
    J Ethnopharmacol, 135(1): 126-34. [Abstract] [Full-text]
62. Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis.
    J Clin Pharmacol, 51(5): 639-48. [Abstract] [Full-text]
63. Primary Sjögren's syndrome with minimal change disease--a case report.
    Kaohsiung J Med Sci, 27(5): 190-4. [Abstract] [Full-text]

© 2004-2012 Rheumatoid Arthritis Research Today. All Rights Reserved.